Filing Flows › Vertex Pharmaceuticals (VRTX) › Recalls, complaints & regulation
Vertex Pharmaceuticals (VRTX): EPA violations, clinical trials and Federal Register
Vertex Pharmaceuticals (VRTX) beyond its filings: 2 EPA-regulated facilities in violation, no penalties in five years; 2 Federal Register documents in a year; 32 active clinical trials.
EPA facilities in violation
| Facility (as registered) | City | Status | Penalties |
|---|---|---|---|
| VERTEX CHEMICAL CORP | Dupo, IL | Significant Violation | — |
| VERTEX REFINING ALABAMA LLC | Saraland, AL | Violation Identified | — |
Facilities in the EPA's ECHO register whose registered name matches the company's; a facility can belong to another business of the same name.
Vertex Pharmaceuticals' latest quarter
Vertex Pharmaceuticals, Q3 2026: revenue $3.4B (+12% year over year), operating margin 20.7%, net earnings $654M, operating cash flow $643M. The chart follows the revenue to costs, profit and cash.
Questions
Has Vertex Pharmaceuticals been fined by the EPA?
The 32 EPA-regulated facilities on file under its name drew no penalties in five years; 2 are in violation now.
How many clinical trials does Vertex Pharmaceuticals have?
32 active studies on ClinicalTrials.gov, 18 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.